Determination of chidamide in rat plasma and cerebrospinal fluid.
Regul Toxicol Pharmacol
; 98: 24-30, 2018 Oct.
Article
em En
| MEDLINE
| ID: mdl-30008379
ABSTRACT
Chidamide is a new subtype-selective histone deacetylase inhibitor (HDACi), which has been approved for the treatment of recurrent or refractory peripheral T-cell lymphoma (PTCL) in China. However, there are few studies about the application of chidamide in PTCL with central nervous system (CNS) involvement. It is essential to investigate the penetration of chidamide in the blood brain barrier (BBB). LC-MS methods were established firstly to determine the concentration of chidamide in rat plasma and CSF. Then five rats were anaesthetized and the plasma and CSF samples were collected at the time of 5, 15, 30, 60, 120, 180, 240, 360 and 480â¯min after being administered 1â¯mg/kg chidamide by intravenous injection, respectively. All samples were analyzed with the established LC-MS method by using the precursor/product transitions (m/z) of 391.1/265.1 for chidamide and 441.1/138.2 for internal standard (IS). The PK parameters were calculated after both of the concentrations of chidamide in plasma and CSF were determined. The penetration ratio of chidamide in BBB ranged from 0.19% to 0.67%. Result indicated chidamide could pass through the BBB, enter into the CNS and have the potential to be utilized in PTCL with CNS involvement.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Benzamidas
/
Inibidores de Histona Desacetilases
/
Aminopiridinas
/
Antineoplásicos
Limite:
Animals
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article